Citation :
Poirier, A., Picard, C., Labonté, A., Aubry, I., Auld, D., Zetterberg, H., Blennow, K., PREVENT-AD research group, Tremblay, M. L., & Poirier, J. (2024). PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease. Scientific reports, 14(1), 14718. https://doi.org/10.1038/s41598-024-65104-2
Full text : Here
Poirier A., Picard C., Labonté A., Auld D., and Alzheimer Disease Neuroimaging Initiative, Zetterberg H., Blennow K., Tremblay M., and Poirier J., for the PREVENT-AD research group
published in Nature Scientific Reports, June 2024.
ABSTRACT:
We examined the role of protein tyrosine phosphatase receptor sigma (PTPRS) in the context of Alzheimer’s disease and synaptic integrity. Publicly available datasets (BRAINEAC, ROSMAP, ADC1) and a cohort of asymptomatic but “at risk” individuals (PREVENT-AD) were used to explore the relationship between PTPRS and various Alzheimer’s disease biomarkers. We identified that PTPRS rs10415488 variant C shows features of neuroprotection against early Tau pathology and synaptic degeneration in Alzheimer’s disease. This single nucleotide polymorphism correlated with higher PTPRS transcript abundance and lower p(181)Tau and GAP-43 levels in the CSF. In the brain, PTPRS protein abundance was significantly correlated with the quantity of two markers of synaptic integrity: SNAP25 and SYT-1. We also found the presence of sexual dimorphism for PTPRS, with higher CSF concentrations in males than females. Male carriers for variant C were found to have a 10-month delay in the onset of AD. We thus conclude that PTPRS acts as a neuroprotective receptor in Alzheimer’s disease. Its protective effect is most important in males, in whom it postpones the age of onset of the disease.